Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LVP-R-G-mIL2
- Development stage
- Preclinical
- Lead developer
- University of Science and Technology of China
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
LVP-R-G-mIL2 is an experimental recombinant oncolytic vaccinia virus (Lister strain) engineered for cancer immunotherapy. It is designed to co-express murine Interleukin-2 (mIL2), the NKG2D ligand RAE-1γ (represented by 'R'), and the tumor-associated antigen gp70 (represented by 'G'). The therapeutic strategy utilizes the virus's inherent oncolytic properties to directly lyse tumor cells while simultaneously delivering immune-modulating payloads. The expression of mIL2 stimulates T-cell and NK-cell proliferation and activity, while RAE-1γ enhances innate immune recognition via the NKG2D receptor. The gp70 antigen provides a specific target for the induction of adaptive anti-tumor immunity. This multi-pronged approach is intended to overcome the immunosuppressive tumor microenvironment, particularly in models of mammary carcinoma such as the 4T1 breast cancer line.
- Other names
- LVP-RAE-1γ-gp70-mIL2Lister Vaccinia Virus-RAE-1γ-gp70-mIL2
02
Targets
gp70 (Feline leukemia virus envelope glycoprotein gp70)IL-2R (Interleukin-2/interleukin-15 receptor complex)NKG2D (Natural killer group 2 member D receptor)
Beyond the preview
Go deeper on LVP-R-G-mIL2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LVP-R-G-mIL2.